Trial Radar
Sign in

NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Long-term Follow-up of Glutamic Acid Decarboxylase (GAD) Gene Transfer in Parkinson's Disease
Long-term Follow-up of Glutamic Acid Decarboxylase (GAD) Gene Transfer in Parkinson's Disease

NCT05894343

Active Not RecruitingPhase 1, Phase 2

Sponsor: MeiraGTx, LLC

Conditions: Parkinson's Disease

Interventions: AAV-GAD

Countries: United States

The objective of this study is to evaluate the long-term safety of AAV-GAD delivered bilaterally to the subthalamic nuclei (STN) in participants with Parkinson's disease.

Eligibility overview

Sex: ALL

Age: 25 Years to 86 Years

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria
Inclusion Criteria:

* Previously enrolled in Study MGT-GAD-025.

Exclusion Criteria:

* None
Locations (6)
  • New Haven, Connecticut, United States
  • West Bloomfield, Michigan, United States
  • New York, New York, United States
  • New York, New York, United States
  • Philadelphia, Pennsylvania, United States
  • Morgantown, West Virginia, United States